Inovio Awarded up to $56 Million from CEPI to Advance DNA Vaccines Against Lassa Fever and MERS
Inovio Pharmaceuticals and CEPI – the Coalition for Epidemic Preparedness Innovations – announced a partnership under which Inovio will develop vaccine candidates against Lassa fever…
Read More...
Read More...
